ApeX Therapeutics, which has received an investment from the Innovate Indiana Fund and licenses technology through Indiana University Research and Technology Corp., has had its Investigational New Drug (IND) application accepted by the U.S. Food and Drug Administration. The company will conduct clinical testing of its lead drug candidate, APX3330, in pancreatic cancer.
Mark R. Kelley, Ph.D., is Scientific Founder of ApeX Therapeutics. He also is the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor of Biochemistry and Molecular Biology and Pharmacology and Toxicology at Indiana University School of Medicine.
“We are very excited to have reached this very important milestone to evaluate APX3330 in patients with pancreatic cancer,” he said. “We are now poised to initiate the study in the coming months.”
More information about the U.S. FDA acceptance of the IND application is here.